392 related articles for article (PubMed ID: 33792208)
1. Serum creatine kinase and creatinine in adult spinal muscular atrophy under nusinersen treatment.
Freigang M; Wurster CD; Hagenacker T; Stolte B; Weiler M; Kamm C; Schreiber-Katz O; Osmanovic A; Petri S; Kowski A; Meyer T; Koch JC; Cordts I; Deschauer M; Lingor P; Aust E; Petzold D; Ludolph AC; Falkenburger B; Hermann A; Günther R
Ann Clin Transl Neurol; 2021 May; 8(5):1049-1063. PubMed ID: 33792208
[TBL] [Abstract][Full Text] [Related]
2. Safety and Treatment Effects of Nusinersen in Longstanding Adult 5q-SMA Type 3 - A Prospective Observational Study.
Walter MC; Wenninger S; Thiele S; Stauber J; Hiebeler M; Greckl E; Stahl K; Pechmann A; Lochmüller H; Kirschner J; Schoser B
J Neuromuscul Dis; 2019; 6(4):453-465. PubMed ID: 31594243
[TBL] [Abstract][Full Text] [Related]
3. Neurofilament light chain in serum of adolescent and adult SMA patients under treatment with nusinersen.
Wurster CD; Steinacker P; Günther R; Koch JC; Lingor P; Uzelac Z; Witzel S; Wollinsky K; Winter B; Osmanovic A; Schreiber-Katz O; Al Shweiki R; Ludolph AC; Petri S; Hermann A; Otto M;
J Neurol; 2020 Jan; 267(1):36-44. PubMed ID: 31552549
[TBL] [Abstract][Full Text] [Related]
4. Serum creatinine is a biomarker of progressive denervation in spinal muscular atrophy.
Alves CRR; Zhang R; Johnstone AJ; Garner R; Nwe PH; Siranosian JJ; Swoboda KJ
Neurology; 2020 Mar; 94(9):e921-e931. PubMed ID: 31882526
[TBL] [Abstract][Full Text] [Related]
5. Nusinersen for adults with spinal muscular atrophy.
Arslan D; Inan B; Kilinc M; Bekircan-Kurt CE; Erdem-Ozdamar S; Tan E
Neurol Sci; 2023 Jul; 44(7):2393-2400. PubMed ID: 36854931
[TBL] [Abstract][Full Text] [Related]
6. Nusinersen treatment of older children and adults with spinal muscular atrophy.
Konersman CG; Ewing E; Yaszay B; Naheedy J; Murphy S; Skalsky A
Neuromuscul Disord; 2021 Mar; 31(3):183-193. PubMed ID: 33608138
[TBL] [Abstract][Full Text] [Related]
7. Prospective Cohort Study of Nusinersen Treatment in Adults with Spinal Muscular Atrophy.
Yeo CJJ; Simeone SD; Townsend EL; Zhang RZ; Swoboda KJ
J Neuromuscul Dis; 2020; 7(3):257-268. PubMed ID: 32333595
[TBL] [Abstract][Full Text] [Related]
8. Neurofilament Levels in CSF and Serum in an Adult SMA Cohort Treated with Nusinersen.
Rich KA; Fox A; Yalvac M; Heintzman S; Tellez M; Bartlett A; Severyn S; Linsenmayer M; Kelly K; Reynolds J; Sterling GB; Weaver T; Rajneesh K; Pino MG; Arnold WD; Elsheikh B; Kolb SJ
J Neuromuscul Dis; 2022; 9(1):111-119. PubMed ID: 34776417
[TBL] [Abstract][Full Text] [Related]
9. Cerebrospinal Fluid and Clinical Profiles in Adult Type 2-3 Spinal Muscular Atrophy Patients Treated with Nusinersen: An 18-Month Single-Centre Experience.
Milella G; Introna A; D'Errico E; Fraddosio A; Scaglione G; Morea A; Ucci M; Ruggieri M; Mastrapasqua M; Megna M; Puntillo F; Simone IL
Clin Drug Investig; 2021 Sep; 41(9):775-784. PubMed ID: 34389971
[TBL] [Abstract][Full Text] [Related]
10. Nusinersen in adult patients with 5q spinal muscular atrophy: A multicenter observational cohorts' study.
Vázquez-Costa JF; Povedano M; Nascimiento-Osorio AE; Moreno Escribano A; Kapetanovic Garcia S; Dominguez R; Exposito JM; González L; Marco C; Medina Castillo J; Muelas N; Natera de Benito D; Ñungo Garzón NC; Pitarch Castellano I; Sevilla T; Hervás D
Eur J Neurol; 2022 Nov; 29(11):3337-3346. PubMed ID: 35872571
[TBL] [Abstract][Full Text] [Related]
11. Assessment of motor function and nutritional status in children with spinal muscular atrophy treated with nusinersen after loading period in Western China: a retrospective study.
Yang H; Tao Q; Li D; Yang J; Cai Q; Gan J; Huang S; Luo R
BMC Neurol; 2023 Jan; 23(1):35. PubMed ID: 36690929
[TBL] [Abstract][Full Text] [Related]
12. Neurological and Psychiatric Aspects of Biological Markers for the Provision of Medical Care to Patients with Spinal Muscular Atrophy 5q.
Gayduk AJ; Syunyakov T; Gazheva AV; Strelnik A; Chigareva O; Kuznetsov A; Kokorev D; Sustretov A; Cumming P; Vlasov YV
Psychiatr Danub; 2023 Oct; 35(Suppl 2):322-328. PubMed ID: 37800249
[TBL] [Abstract][Full Text] [Related]
13. Cerebrospinal fluid proteomic profiling in nusinersen-treated patients with spinal muscular atrophy.
Kessler T; Latzer P; Schmid D; Warnken U; Saffari A; Ziegler A; Kollmer J; Möhlenbruch M; Ulfert C; Herweh C; Wildemann B; Wick W; Weiler M
J Neurochem; 2020 Jun; 153(5):650-661. PubMed ID: 31903607
[TBL] [Abstract][Full Text] [Related]
14. Treatment expectations and perception of therapy in adult patients with spinal muscular atrophy receiving nusinersen.
Meyer T; Maier A; Uzelac Z; Hagenacker T; Günther R; Schreiber-Katz O; Weiler M; Steinbach R; Weyen U; Koch JC; Kettemann D; Norden J; Dorst J; Wurster C; Ludolph AC; Stolte B; Freigang M; Osmanovic A; Petri S; Grosskreutz J; Rödiger A; Griep R; Gaudlitz M; Walter B; Münch C; Spittel S
Eur J Neurol; 2021 Aug; 28(8):2582-2595. PubMed ID: 33960080
[TBL] [Abstract][Full Text] [Related]
15. Muscle and not neuronal biomarkers correlate with severity in spinal and bulbar muscular atrophy.
Lombardi V; Querin G; Ziff OJ; Zampedri L; Martinelli I; Heller C; Foiani M; Bertolin C; Lu CH; Malik B; Allen K; Rinaldi C; Zetterberg H; Heslegrave A; Greensmith L; Hanna M; Soraru G; Malaspina A; Fratta P
Neurology; 2019 Mar; 92(11):e1205-e1211. PubMed ID: 30787165
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of nusinersen in type 1, 2 and 3 spinal muscular atrophy: Real world data from Hungarian patients.
Szabó L; Gergely A; Jakus R; Fogarasi A; Grosz Z; Molnár MJ; Andor I; Schulcz O; Goschler Á; Medveczky E; Czövek D; Herczegfalvi Á
Eur J Paediatr Neurol; 2020 Jul; 27():37-42. PubMed ID: 32456992
[TBL] [Abstract][Full Text] [Related]
17. Risdiplam improves subjective swallowing quality in non-ambulatory adult patients with 5q-spinal muscular atrophy despite advanced motor impairment.
Brakemeier S; Lipka J; Schlag M; Kleinschnitz C; Hagenacker T
J Neurol; 2024 May; 271(5):2649-2657. PubMed ID: 38358553
[TBL] [Abstract][Full Text] [Related]
18. Real-World Data from Nusinersen Treatment for Patients with Later-Onset Spinal Muscular Atrophy: A Single Center Experience.
Mendonça RH; Polido GJ; Matsui C; Silva AMS; Solla DJF; Reed UC; Zanoteli E
J Neuromuscul Dis; 2021; 8(1):101-108. PubMed ID: 33074187
[TBL] [Abstract][Full Text] [Related]
19. Effect of Nusinersen in a late onset spinal muscular atrophy patient for 14 months: A case report.
Park JM; Min YS; Park D; Park JS
Medicine (Baltimore); 2021 Jan; 100(1):e24236. PubMed ID: 33429824
[TBL] [Abstract][Full Text] [Related]
20. An observational cohort study on pulmonary function in adult patients with 5q-spinal muscular atrophy under nusinersen therapy.
Bjelica B; Wohnrade C; Osmanovic A; Schreiber-Katz O; Petri S
J Neurol; 2023 Jul; 270(7):3616-3622. PubMed ID: 37062018
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
